Agendia Presents Data from Innovative FLEX Study at ASCO 2021 Showing MammaPrint and BluePrint Utility in Wide Variety of Patient Populations
Transcriptomic differences found between Luminal tumors in African American and Read More
ASCO 2021 Podium Presentation on Agendia FLEX Study Shows Clinical & Molecular Differences in Tumors of African American and Caucasian Patients with HR+ Breast Cancer, Underscores Importance of Genomic Insights to Understand Disparities in Outcomes
Transcriptomic differences found between Luminal tumors in African American and Read More
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Read More
Landmark Long-Term Data from EORTC’s MINDACT Study Published in The Lancet Oncology
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – March 12, 2021 Read More
Data Presented at the Miami Breast Cancer Conference Show MammaPrint® and BluePrint® Accurately Predict Pathologic Complete Response Rate Regardless of Age
Results support use of Agendia’s genomic tests to better tailor Read More
Agendia to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Agendia to Participate in the BTIG MedTech, Digital Health, Life Read More
Agendia to Participate in the 39th Annual J.P. Morgan Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology Read More
Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint for Clinical Low Risk Breast Cancer Patients at SABCS 2020
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 11, 2020 Read More
Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint
Clinical utility of molecular subtyping and risk of recurrence profiling Read More
Results from APHINITY Trial using BluePrint as a Biomarker Assay Presented at SABCS in Poster Spotlight Discussion
Agendia and Roche evaluate BluePrint’s stratification of HER2+ early breast Read More
